Characterization and function of human ly-6/upar molecules

BMB Reports

Volumn 45, Issue 11, 2012, Pages 595-603

  Kong, Hyun Kyung ^a   Park, Jong Hoon ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Cancer metastasis; Cancer therapy; Gene family; Hematopoiesis; Immune system; Tumorigenesis

Indexed keywords

LY ANTIGEN; UROKINASE;

AMINO ACID SEQUENCE; ANIMAL; HUMAN; METABOLISM; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; SHORT SURVEY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, LY; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84871425009     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2012.45.11.210     Document Type: Short Survey

References (100)

1. McKenzie, I. F., Gardiner, J., Cherry, M. and Snell, G. D. (1977) Lymphocyte antigens: Ly-4, Ly-6, and Ly-7. Transplant Proc. 9, 667-669.
2. LeClair, K. P., Rabin, M., Nesbitt, M. N., Pravtcheva, D., Ruddle, F. H., Palfree, R. G. and Bothwell, A. (1987) Murine Ly-6 multigene family is located on chromosome 15. Proc. Natl. Acad. Sci. U.S.A. 84, 1638-1642.
3. Gumley, T. P., McKenzie, I. F. and Sandrin, M. S. (1995) Tissue expression, structure and function of the murine Ly-6 family of molecules. Immunol. Cell. Biol. 73, 277-296.
4. Li, S. H., Lee, R. K., Lin, M. H., Hwu, Y. M., Lu, C. H., Chen, Y. J., Chen, H. C., Chang, W. H. and Chang, W. C. (2006) SSLP-1, a secreted Ly-6 protein purified from mouse seminal vesicle fluid. Reproduction 132, 493-500.
5. Havran, W. L., Lancki, D. W., Moldwin, R. L., Dialynas, D. P. and Fitch, F. W. (1988) Characterization of an anti- Ly-6 monoclonal antibody which defines and activates cytolytic T lymphocytes. J. Immunol. 140, 1034-1042.
6. Davies, A., Simmons, D. L., Hale, G., Harrison, R. A., Tighe, H., Lachmann, P. J. and Waldmann, H. (1989) CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J. Exp. Med. 170, 637-654.
7. Fleming, T. J., O'HUigin, C. and Malek, T. R. (1993) Characterization of two novel Ly-6 genes. Protein sequence and potential structural similarity to alpha-bungarotoxin and other neurotoxins. J. Immunol. 150, 5379-5390.
8. Meri, S., Morgan, B. P., Davies, A., Daniels, R. H., Olavesen, M. G., Waldmann, H. and Lachmann, P. J. (1990) Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71, 1-9.
9. Chang, C. P., Husler, T., Zhao, J., Wiedmer, T. and Sims, P. J. (1994) Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59. J. Biol. Chem. 269, 26424-26430.
10. Treon, S. P., Shima, Y., Grossbard, M. L., Preffer, F. I., Belch, A. R., Pilarski, L. M. and Anderson, K. C. (2000) Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann. Oncol. 11(Suppl 1), 107-111.
11. Naderi, S., Hofmann, P., Seiter, S., Tilgen, W., Abken, H. and Reinhold, U. (1999) CD2-mediated CD59 stimulation in keratinocytes results in secretion of IL-1alpha, IL-6, and GM-CSF: implications for the interaction of keratinocytes with intraepidermal T lymphocytes. Int. J. Mol. Med. 3,609-614.
12. Li, B., Chu, X., Gao, M. and Xu, Y. (2011) The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol. 272, 61-70.
13. Temerinac, S., Klippel, S., Strunck, E., Roder, S., Lubbert, M., Lange, W., Azemar, M., Meinhardt, G., Schaefer, H. E. and Pahl, H. L. (2000) Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood 95, 2569-2576.
14. Sachs, U. J., Andrei-Selmer, C. L., Maniar, A., Weiss, T., Paddock, C., Orlova, V. V., Choi, E. Y., Newman, P. J., Preissner, K. T., Chavakis, T. and Santoso, S. (2007) The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J. Biol. Chem. 282, 23603-23612.
15. Dillon, M., Minear, J., Johnson, J. and Lannutti, B. J. (2008) Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines. Leuk Res. 32, 811-819.
16. Korkmaz, B., Kuhl, A., Bayat, B., Santoso, S. and Jenne, D. E. (2008) A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. J. Biol. Chem. 283, 35976-35982.
17. Beigneux, A. P., Davies, B. S., Gin, P., Weinstein, M. M., Farber, E., Qiao, X., Peale, F., Bunting, S., Walzem, R. L., Wong, J. S., Blaner, W. S., Ding, Z. M., Melford, K., Wongsiriroj, N., Shu, X., de Sauvage, F., Ryan, R. O., Fong, L. G., Bensadoun, A. and Young, S. G. (2007) Glycosylphosphatidylinositol-anchored high-density lipoprotein- binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 5, 279-291.
18. Davies, B. S., Beigneux, A. P., Barnes, R. H. 2nd, Tu, Y., Gin, P., Weinstein, M. M., Nobumori, C., Nyren, R., Goldberg, I., Olivecrona, G., Bensadoun, A., Young, S. G. and Fong, L. G. (2010) GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab. 12, 42-52.
19. Quak, J. J., Balm, A. J., van Dongen, G. A., Brakkee, J. G., Scheper, R. J., Snow, G. B. and Meijer, C. J. (1990) A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am. J. Pathol. 136, 191-197.
20. Bartelink, H. and Keus, R. B. (1991) Progress in radiotherapy by treatment tailoring in head and neck cancer. Curr. Opin. Oncol. 3, 523-528.
21. Nieuwenhuis, E. J., Leemans, C. R., Kummer, J. A., Denkers, F., Snow, G. B. and Brakenhoff, R. H. (2003) Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction. Lab. Invest. 83, 1233-1240.
22. Antica, M., Wu, L. and Scollay, R. (1997) Stem cell antigen 2 expression in adult and developing mice. Immunol. Lett. 55, 47-51.
23. Noda, S., Kosugi, A., Saitoh, S., Narumiya, S. and Hamaoka, T. (1996) Protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal through thymic shared antigen-1/stem cell antigen-2. J. Exp. Med. 183, 2355-2360.
24. Saitoh, S., Kosugi, A., Noda, S., Yamamoto, N., Ogata, M., Minami, Y., Miyake, K. and Hamaoka, T. (1995) Modulation of TCR-mediated signaling pathway by thymic shared antigen-1 (TSA-1)/stem cell antigen-2 (Sca-2). J. Immunol. 155, 5574-5581.
25. Bresson-Mazet, C., Gandrillon, O. and Gonin-Giraud, S. (2008) Stem cell antigen 2: a new gene involved in the self-renewal of erythroid progenitors. Cell Prolif. 41, 726-738.
26. Horie, M., Okutomi, K., Taniguchi, Y., Ohbuchi, Y., Suzuki, M. and Takahashi, E. (1998) Isolation and characterization of a new member of the human Ly6 gene family (LY6H). Genomics 53, 365-368.
27. de Nooij-van Dalen, A. G., van Dongen, G. A., Smeets, S. J., Nieuwenhuis, E. J., Stigter-van Walsum, M., Snow, G. B. and Brakenhoff, R. H. (2003) Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma. Int. J. Cancer 103, 768-774.
28. Lee, J. W., Lee, Y. S., Yoo, K. H., Lee, K. H., Park, K., Ahn, T., Ko, C. and Park, J. H. (2006) LY-6K gene: a novel molecular marker for human breast cancer. Oncol. Rep. 16, 1211-1214.
29. Ishikawa, N., Takano, A., Yasui, W., Inai, K., Nishimura, H., Ito, H., Miyagi, Y., Nakayama, H., Fujita, M., Hosokawa, M., Tsuchiya, E., Kohno, N., Nakamura, Y. and Daigo, Y. (2007) Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 67, 11601-11611.
30. Matsuda, R., Enokida, H., Chiyomaru, T., Kikkawa, N., Sugimoto, T., Kawakami, K., Tatarano, S., Yoshino, H., Toki, K., Uchida, Y., Kawahara, K., Nishiyama, K., Seki, N. and Nakagawa, M. (2011) LY6K is a novel molecular target in bladder cancer on basis of integrate genome- wide profiling. Br. J. Cancer 104, 376-386.
31. Zhang, B., Zhang, Z., Zhang, X., Gao, X., Kernstine, K. H. and Zhong, L. (2012) Serological antibodies against LY6K as a diagnostic biomarker in esophageal squamous cell carcinoma. Biomarkers 17, 372-378.
32. Choi, S. H., Kong, H. K., Park, S. Y. and Park, J. H. (2009) Metastatic effect of LY-6K gene in breast cancer cells. Int. J. Oncol. 35, 601-607.
33. Suda, T., Tsunoda, T., Daigo, Y., Nakamura, Y. and Tahara, H. (2007) Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 98, 1803-1808.
34. Yu, D. H., Fan, W., Liu, G., Nguy, V., Chatterton, J. E., Long, S., Ke, N., Meyhack, B., Bruengger, A., Brachat, A., Wong-Staal, F. and Li, Q. X. (2006) PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway. Exp. Cell Res. 312, 865-876.
35. Egerod, K. L., Holst, B., Petersen, P. S., Hansen, J. B., Mulder, J., Hokfelt, T. and Schwartz, T. W. (2007) GPR39 splice variants versus antisense gene LYPD1: expression and regulation in gastrointestinal tract, endocrine pancreas, liver, and white adipose tissue. Mol. Endocrinol. 21, 1685-1698.
36. Wurfel, J., Seiter, S., Stassar, M., Claas, A., Klas, R., Rosel, M., Marhaba, R., Savelyeva, L., Schwab, M., Matzku, S. and Zoller, M. (2001) Cloning of the human homologue of the metastasis-associated rat C4.4A. Gene 262, 35-41.
37. Seiter, S., Stassar, M., Rappl, G., Reinhold, U., Tilgen, W. and Zoller, M. (2001) Upregulation of C4.4A expression during progression of melanoma. J. Invest. Dermatol. 116, 344-347.
38. Fletcher, G. C., Patel, S., Tyson, K., Adam, P. J., Schenker, M., Loader, J. A., Daviet, L., Legrain, P., Parekh, R., Harris, A. L. and Terrett, J. A. (2003) hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br. J. Cancer 88, 579-585.
39. Paret, C., Hildebrand, D., Weitz, J., Kopp-Schneider, A., Kuhn, A., Beer, A., Hautmann, R. and Zoller, M. (2007) C4.4A as a candidate marker in the diagnosis of colorectal cancer. Br. J. Cancer 97, 1146-1156.
40. Hansen, L. V., Skov, B. G., Ploug, M. and Pappot, H. (2007) Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer. Lung Cancer 58, 260-266.
41. Hansen, L. V., Laerum, O. D., Illemann, M., Nielsen, B. S. and Ploug, M. (2008) Altered expression of the urokinase receptor homologue, C4.4A, in invasive areas of human esophageal squamous cell carcinoma. Int. J. Cancer 122, 734-741.
42. Oshiro, R., Yamamoto, H., Takahashi, H., Ohtsuka, M., Wu, X., Nishimura, J., Takemasa, I., Mizushima, T., Ikeda, M., Sekimoto, M., Matsuura, N., Doki, Y. and Mori, M. (2012) C4.4A is associated with tumor budding and epithelial- mesenchymal transition of colorectal cancer. Cancer Sci. 103, 1155-1164.
43. Ngora, H., Galli, U. M., Miyazaki, K. and Zoller, M. (2012) Membrane-bound and exosomal metastasis-associated C4.4A promotes migration by associating with the alpha(6)beta(4) integrin and MT1-MMP. Neoplasia 14, 95-107.
44. Zhang, Y., Lang, Q., Li, J., Xie, F., Wan, B. and Yu, L. (2010) Identification and characterization of human LYPD6, a new member of the Ly-6 superfamily. Mol. Biol. Rep. 37, 2055-2062.
45. Ni, J., Lang, Q., Bai, M., Zhong, C., Chen, X., Wan, B. and Yu, L. (2009) Cloning and characterization of a human LYPD7, a new member of the Ly-6 superfamily. Mol. Biol. Rep. 36, 697-703.
46. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., Loda, M. and Witte, O. N. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 95, 1735-1740.
47. Argani, P., Rosty, C., Reiter, R. E., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Ryu, B., Skinner, H. G., Goggins, M., Jaffee, E. M., Yeo, C. J., Cameron, J. L., Kern, S. E. and Hruban, R. H. (2001) Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61, 4320-4324.
48. Amara, N., Palapattu, G. S., Schrage, M., Gu, Z., Thomas, G. V., Dorey, F., Said, J. and Reiter, R. E. (2001) Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 61, 4660-4665.
49. Elsamman, E. M., Fukumori, T., Tanimoto, S., Nakanishi, R., Takahashi, M., Toida, K. and Kanayama, H. O. (2006) The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase- polymerase chain reaction analysis. BJU Int. 98, 668-673.
50. Sakamoto, H., Yoshimura, K., Saeki, N., Katai, H., Shimoda, T., Matsuno, Y., Saito, D., Sugimura, H., Tanioka, F., Kato, S., Matsukura, N., Matsuda, N., Nakamura, T., Hyodo, I., Nishina, T., Yasui, W., Hirose, H., Hayashi, M., Toshiro, E., Ohnami, S., Sekine, A., Sato, Y., Totsuka, H., Ando, M., Takemura, R., Takahashi, Y., Ohdaira, M., Aoki, K., Honmyo, I., Chiku, S., Aoyagi, K., Sasaki, H., Yanagihara, K., Yoon, K. A., Kook, M. C., Lee, Y. S., Park, S. R., Kim, C. G., Choi, I. J., Yoshida, T., Nakamura, Y. and Hirohashi, S. (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40, 730-740.
51. Liu, W. K., Jiang, X. Y. and Zhang, Z. X. (2010) Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie 33, 241-245.
52. Kawaguchi, T., Sho, M., Tojo, T., Yamato, I., Nomi, T., Hotta, K., Hamada, K., Suzaki, Y., Sugiura, S., Kushibe, K., Nakajima, Y. and Taniguchi, S. (2010) Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn. J. Clin. Oncol. 40, 319-326.
53. Liu, W. K., Jiang, X. Y. and Zhang, Z. X. (2010) Expression of PSCA, PIWIL1 and TBX2 and its correlation with HPV16 infection in formalin-fixed, paraffin-embedded cervical squamous cell carcinoma specimens. Arch. Virol. 155, 657-663.
54. Hao, J. Y., Yang, Y. L., Li, S., Qian, X. L., Liu, F. F. and Fu, L. (2011) PSCA expression in invasive micropapillary carcinoma of breast. Zhonghua Bing Li Xue Za Zhi 40, 382-386.
55. Geiger, K. D., Hendruschk, S., Rieber, E. P., Morgenroth, A., Weigle, B., Juratli, T., Senner, V., Schackert, G. and Temme, A. (2011) The prostate stem cell antigen represents a novel glioma-associated antigen. Oncol Rep. 26, 13-21.
56. Bahrenberg, G., Brauers, A., Joost, H. G. and Jakse, G. (2000) Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. Biochem. Biophys. Res. Commun. 275, 783-788.
57. Ono, H., Hiraoka, N., Lee, Y. S., Woo, S. M., Lee, W. J., Choi, I. J., Saito, A., Yanagihara, K., Kanai, Y., Ohnami, S., Chiwaki, F., Sasaki, H., Sakamoto, H., Yoshida, T. and Saeki, N. (2012) Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer 51, 30-41.
58. Wu, X., Ye, Y., Kiemeney, L. A., Sulem, P., Rafnar, T., Matullo, G., Seminara, D., Yoshida, T., Saeki, N., Andrew, A. S., Dinney, C. P., Czerniak, B., Zhang, Z. F., Kiltie, A. E., Bishop, D. T., Vineis, P., Porru, S., Buntinx, F., Kellen, E., Zeegers, M. P., Kumar, R., Rudnai, P., Gurzau, E., Koppova, K., Mayordomo, J. I., Sanchez, M., Saez, B., Lindblom, A., de Verdier, P., Steineck, G., Mills, G. B., Schned, A., Guarrera, S., Polidoro, S., Chang, S. C., Lin, J., Chang, D. W., Hale, K. S., Majewski, T., Grossman, H. B., Thorlacius, S., Thorsteinsdottir, U., Aben, K. K., Witjes, J. A., Stefansson, K., Amos, C. I., Karagas, M. R. and Gu, J. (2009) Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat. Genet. 41, 991-995.
59. Matsuo, K., Tajima, K., Suzuki, T., Kawase, T., Watanabe, M., Shitara, K., Misawa, K., Ito, S., Sawaki, A., Muro, K., Nakamura, T., Yamao, K., Yamamura, Y., Hamajima, N., Hiraki, A. and Tanaka, H. (2009) Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. Int. J. Cancer 125, 1961-1964.
60. Kim, S. Y., Yoo, J. Y., Shin, A., Kim, Y., Lee, E. S. and Lee, Y. S. (2012) Prostate stem cell antigen single nucleotide polymorphisms influence risk of estrogen receptor negative breast cancer in Korean females. Asian Pac. J. Cancer Prev. 13, 41-48.
61. Saffran, D. C., Raitano, A. B., Hubert, R. S., Witte, O. N., Reiter, R. E. and Jakobovits, A. (2001) Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. U.S.A. 98, 2658-2663.
62. Feng, H. C., Tsao, S. W., Ngan, H. Y., Xue, W. C., Kwan, H. S., Siu, M. K., Liao, X. Y., Wong, E. and Cheung, A. N. (2008) Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia. Histopathology 52, 167-174.
63. Moore, M. L., Teitell, M. A., Kim, Y., Watabe, T., Reiter, R. E., Witte, O. N. and Dubey, P. (2008) Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 68, 139-151.
64. Marra, E., Uva, P., Viti, V., Simonelli, V., Dogliotti, E., De Rinaldis, E., Lahm, A., La Monica, N., Nicosia, A., Ciliberto, G. and Palombo, F. (2010) Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer 10, 129.
65. Shetty, J., Wolkowicz, M. J., Digilio, L. C., Klotz, K. L., Jayes, F. L., Diekman, A. B., Westbrook, V. A., Farris, E. M., Hao, Z., Coonrod, S. A., Flickinger, C. J. and Herr, J. C. (2003) SAMP14, a novel, acrosomal membrane-associated, glycosylphosphatidylinositol-anchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm-egg interaction. J. Biol. Chem. 278, 30506-30515.
66. Adermann, K., Wattler, F., Wattler, S., Heine, G., Meyer, M., Forssmann, W. G. and Nehls, M. (1999) Structural and phylogenetic characterization of human SLURP-1, the first secreted mammalian member of the Ly-6/uPAR protein superfamily. Protein. Sci. 8, 810-819.
67. Fischer, J., Bouadjar, B., Heilig, R., Huber, M., Lefevre, C., Jobard, F., Macari, F., Bakija-Konsuo, A., Ait-Belkacem, F., Weissenbach, J., Lathrop, M., Hohl, D. and Prud'homme, J. F. (2001) Mutations in the gene encoding SLURP-1 in Mal de Meleda. Hum. Mol. Genet 10, 875-880.
68. Tsuji, H., Okamoto, K., Matsuzaka, Y., Iizuka, H., Tamiya, G. and Inoko, H. (2003) SLURP-2, a novel member of the human Ly-6 superfamily that is up-regulated in psoriasis vulgaris. Genomics 81, 26-33.
69. Arredondo, J., Chernyavsky, A. I., Webber, R. J. and Grando, S. A. (2005) Biological effects of SLURP-1 on human keratinocytes. J. Invest. Dermatol. 125, 1236-1241.
70. Pettersson, A., Nordlander, S., Nylund, G., Khorram-Manesh, A., Nordgren, S. and Delbro, D. S. (2008) Expression of the endogenous, nicotinic acetylcholine receptor ligand, SLURP-1, in human colon cancer. Auton Autacoid. Pharmacol. 28, 109-116.
71. Phan, T. C., Ooi, J. and Goonewardene, M. S. (2010) A novel molecule, SLURP-1, enhances the survival of periodontal ligament fibroblasts. J. Periodontal. Res. 45, 331-336.
72. Tjiu, J. W., Lin, P. J., Wu, W. H., Cheng, Y. P., Chiu, H. C., Thong, H. Y., Chiang, B. L., Yang, W. S. and Jee, S. H. (2011) SLURP1 mutation-impaired T-cell activation in a family with mal de Meleda. Br. J. Dermatol. 164, 47-53.
73. Arredondo, J., Chernyavsky, A. I., Jolkovsky, D. L., Webber, R. J. and Grando, S. A. (2006) SLURP-2: A novel cholinergic signaling peptide in human mucocutaneous epithelium. J. Cell. Physiol. 208, 238-245.
74. Moriwaki, Y., Yoshikawa, K., Fukuda, H., Fujii, Y. X., Misawa, H. and Kawashima, K. (2007) Immune system expression of SLURP-1 and SLURP-2, two endogenous nicotinic acetylcholine receptor ligands. Life Sci. 80, 2365-2368.
75. Anderson, D. J., Johnson, P. M., Alexander, N. J., Jones, W. R. and Griffin, P. D. (1987) Monoclonal antibodies to human trophoblast and sperm antigens: report of two WHO-sponsored workshops, June 30, 1986--Toronto, Canada. J. Reprod. Immunol. 10, 231-257.
76. Herr, J. C., Flickinger, C. J., Homyk, M., Klotz, K. and John, E. (1990) Biochemical and morphological characterization of the intra-acrosomal antigen SP-10 from human sperm. Biol. Reprod. 42, 181-193.
77. Kurth, B. E., Klotz, K., Flickinger, C. J. and Herr, J. C. (1991) Localization of sperm antigen SP-10 during the six stages of the cycle of the seminiferous epithelium in man. Biol. Reprod. 44, 814-821.
78. Vassalli, J. D., Baccino, D. and Belin, D. (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100, 86-92.
79. Mondino, A., Resnati, M. and Blasi, F. (1999) Structure and function of the urokinase receptor. Thromb Haemost 82(Suppl 1), 19-22.
80. Schlechte, W., Murano, G. and Boyd, D. (1989) Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 49, 6064-6069.
81. Del Vecchio, S., Stoppelli, M. P., Carriero, M. V., Fonti, R., Massa, O., Li, P. Y., Botti, G., Cerra, M., D'Aiuto, G., Esposito, G. and Salvatore, M. (1993) Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res. 53, 3198-3206.
82. de Vries, T. J., Quax, P. H., Denijn, M., Verrijp, K. N., Verheijen, J. H., Verspaget, H. W., Weidle, U. H., Ruiter, D. J. and van Muijen, G. N. (1994) Plasminogen activa tors, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol. 144, 70-81.
83. Mohanam, S., Sawaya, R. E., Yamamoto, M., Bruner, J. M., Nicholson, G. L. and Rao, J. S. (1994) Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. J. Neurooncol. 22, 153-160.
84. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Ronne, E., Hansen, H. H., Dano, K. and Grondahl-Hansen, J. (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54, 4671-4675.
85. Wagner, S. N., Atkinson, M. J., Thanner, S., Wagner, C., Schmitt, M., Wilhelm, O., Rotter, M. and Hofler, H. (1995) Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am. J. Pathol. 147, 183-192.
86. Morita, Y., Hayashi, Y., Wang, Y., Kanamaru, T., Suzuki, S., Kawasaki, K., Ohta, K., Yamamoto, M., Saitoh, Y., Itoh, H. and Doe, W. F. (1997) Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology 25, 856-861.
87. Yonemura, Y., Nojima, N., Kawamura, T., Ajisaka, H., Taniguchi, K., Fujimura, T., Fujita, H., Bandou, E., Fushida, S., Endou, Y., Obata, T. and Sasaki, T. (1997) Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma. Oncol. Rep. 4, 1229-1234.
88. Sier, C. F., Stephens, R., Bizik, J., Mariani, A., Bassan, M., Pedersen, N., Frigerio, L., Ferrari, A., Dano, K., Brunner, N. and Blasi, F. (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 58, 1843-1849.
89. Schmidt, M. and Hoppe, F. (1999) Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients. Acta. Otolaryngol. 119, 949-953.
90. Nozaki, S., Endo, Y., Nakahara, H., Yoshizawa, K., Hashiba, Y., Kawashiri, S., Tanaka, A., Nakagawa, K., Matsuoka, Y., Kogo, M. and Yamamoto, E. (2005) Inhibition of invasion and metastasis in oral cancer by targeting urokinase- type plasminogen activator receptor. Oral Oncol. 41, 971-977.
91. Wang, J., Guo, F., Wei, H., Dong, J. and Wu, J. (2006) Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma. Br. J. Oral. Maxillofac. Surg. 44, 515-519.
92. Hildenbrand, R., Niedergethmann, M., Marx, A., Belharazem, D., Allgayer, H., Schleger, C. and Strobel, P. (2009) Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am. J. Pathol. 174, 2246-2253.
93. Ossowski, L. and Aguirre-Ghiso, J. A. (2000) Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 12, 613-620.
94. Nykjaer, A., Moller, B., Todd, R. F. 3rd, Christensen, T., Andreasen, P. A., Gliemann, J. and Petersen, C. M. (1994) Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 152, 505-516.
95. Gyetko, M. R., Sitrin, R. G., Fuller, J. A., Todd, R. F. 3rd, Petty, H. and Standiford, T. J. (1995) Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J. Leukoc. Biol. 58, 533-538.
96. Pedersen, N., Schmitt, M., Ronne, E., Nicoletti, M. I., Hoyer-Hansen, G., Conese, M., Giavazzi, R., Dano, K., Kuhn, W., Janicke, F. and Blasi F. (1993) A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J. Clin. Invest. 92, 2160-2167.
97. Rigolin, G. M., Tieghi, A., Ciccone, M., Bragotti, L. Z., Cavazzini, F., Della Porta, M., Castagnari, B., Carroccia, R., Guerra, G., Cuneo, A. and Castoldi, G. (2003) Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra- bone marrow involvement in multiple myeloma patients. Br. J. Haematol. 120, 953-959.
98. Nijziel, M. R., Van Oerle, R., Hellenbrand, D., Van Pampus, E. C., Hillen, H. F. and Hamulyak, K. (2003) The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J. Thromb. Haemost. 1, 982-986.
99. Saitou, N. and Nei, M. (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406-425.
100. Whelan, S. and Goldman, N. (2001) A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach. Mol. Biol. Evol. 18, 691-699.